Antifungal resistance to
Candida
pathogens increases morbidity and mortality of immunosuppressive patients, an emerging crisis worldwide. Understanding the
Candida
prevalence and antifungal susceptibility pattern is necessary to control and treat candidiasis. We aimed to systematically analyse the susceptibility profiles of
Candida
species published in the last ten years (December 2011 to December 2021) from mainland China. The studies were collected from PubMed, Google Scholar, and Science Direct search engines. Out of 89 included studies, a total of 44,716
Candida
isolates were collected, mainly comprising
C. albicans
(49.36%),
C. tropicalis
(21.89%),
C. parapsilosis
(13.92%), and
C. glabrata
(11.37%). The lowest susceptibility was detected for azole group; fluconazole susceptibilities against
C. parapsilosis, C. albicans, C. glabrata, C. tropicalis, C. guilliermondii, C. pelliculosa
, and
C. auris
were 93.25%, 91.6%, 79.4%, 77.95%, 76%, 50%, and 0% respectively. Amphotericin B and anidulafungin were the most susceptible drugs for all
Candida
species. Resistance to azole was mainly linked with mutations in
ERG11, ERG3, ERG4, MRR1–2, MSH-2
, and
PDR-1
genes. Mutation in
FKS-1
and
FKS-2
in
C. auris
and
C. glabrata
causing resistance to echinocandins was stated in two studies. Gaps in the studies’ characteristics were detected, such as 79.77%, 47.19 %, 26.97%, 7.86%, and 4.49% studies did not mention the mortality rates, age, gender, breakpoint reference guidelines, and fungal identification method, respectively. The current study demonstrates the overall antifungal susceptibility pattern of
Candida
species, gaps in surveillance studies and risk-reduction strategies that could be supportive in candidiasis therapy and for the researchers in their future studies.